A socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Roscongress Foundation – a socially oriented non-financial development institution and a major organizer of international conventions, congress, exhibitions, business, social and sporting, public, and cultural events.

The Foundation was established in 2007 with the aim of facilitating the development of Russia’s economic potential, promoting its national interests, and strengthening the country’s image. One of the roles of the Foundation is to comprehensively evaluate, analyse, and cover issues on the Russian and global economic agendas. It also offers administrative services, provides promotional support for business projects and attracting investment, and helps foster social entrepreneurship and charitable initiatives.

Each year, the Foundation’s events draw participants from 208 countries and territories, with more than 15,000 media representatives working on-site at Roscongress’ various venues. The Foundation benefits from analytical and professional expertise provided by 5000 people working in Russia and abroad. In addition, it works in close cooperation with 126 economic partners; industrialists’ and entrepreneurs’ unions; and financial, trade, and business associations from 69 countries worldwide.

RC personal account
Восстановление пароля
Введите адрес электронной почты или телефон, указанные при регистрации. Вам будет отправлена инструкция по восстановлению пароля.
Некорректный формат электронной почты или телефона
Boris  Afanasyev

Boris Afanasyev

Director, Rаisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Haematology and Transplantation
Quotes
24.05.2018
SPIEF 2018
Business, Science, and Practice: Securing Next Generation Healthcare
There is no laboratorial platform by which to individualize patients. <...> As for allogeneic transplantation, there is no national donor register
24.05.2018
SPIEF 2018
Business, Science, and Practice: Securing Next Generation Healthcare
Currently, procurement of immunotherapeutic drugs accounts for 38% of all expenses on purchasing oncological medications. According to some forecasts, this figure will reach USD 100 billion in 2022